Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.

Haass, Nikolas K., Nassif, Najah and McGowan, Eileen M. (2015) Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.. BioMed Research International, 2015 165105.1-165105.9. doi:10.1155/2015/165105

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ351355_OA.pdf Open access application/pdf 1.36MB 11

Author Haass, Nikolas K.
Nassif, Najah
McGowan, Eileen M.
Title Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.
Journal name BioMed Research International   Check publisher's open access policy
ISSN 2314-6133
2314-6141
Publication date 2015
Year available 2014
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1155/2015/165105
Open Access Status DOI
Volume 2015
Start page 165105.1
End page 165105.9
Total pages 9
Place of publication New York, NY, United States
Publisher Hindawi Publishing Corporation
Collection year 2015
Language eng
Formatted abstract
Cancer and diabetes are among the most common diseases in western societies. Epidemiological studies have shown that diabetic patients have a significantly higher risk of developing a number of different types of cancers and that individuals with comorbidity (cancer and diabetes/prediabetes) have a poorer prognosis relative to nondiabetic cancer patients. The increasing frequency of comorbidity of cancer and diabetes mellitus, mainly type 2 diabetes, has driven the development of therapeutic interventions that target both disease states. There is strong evidence to suggest that balancing the sphingolipid rheostat, ceramide—sphingosine—sphingosine-1-phosphate (S1P) is crucial in the prevention of diabetes and cancer and sphingosine kinase/S1P modulators are currently under development for the treatment of cancer and diabetes. This paper will highlight some of the complexities inherent in the use of the emerging sphingosine kinase/S1P modulators in the treatment of comorbidity of diabetes and cancer.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2015 Collection
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Wed, 11 Feb 2015, 23:08:43 EST by Nikolas Haass on behalf of UQ Diamantina Institute